CSF 5-HIAA, attempted suicide and suicide risk in schizophrenia spectrum psychosis

Schizophrenia Research

Volumn 112, Issue 1-3, 2009, Pages 80-85

  Carlborg, Andreas ^a   Jokinen, Jussi ^a   Nordström, Anna Lena ^a   Jönsson, Erik G ^a   Nordström, Peter ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

5 Hydroxyindoleacetic acid (5 HIAA); Gender; Homovanillic acid (HVA); Psychosis; Schizophrenia; Suicide

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; HOMOVANILLIC ACID; MONOAMINE;

ADULT; ARTICLE; CAUSE OF DEATH; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HOSPITAL PATIENT; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENTAL PATIENT; MOOD DISORDER; POLAND; PRIORITY JOURNAL; PSYCHOSIS; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SUICIDAL BEHAVIOR; SUICIDE; SUICIDE ATTEMPT; UNIVERSITY HOSPITAL;

ADULT; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYINDOLEACETIC ACID; MALE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEX FACTORS; SUICIDE, ATTEMPTED; YOUNG ADULT;

EID: 67349096038     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2009.04.006     Document Type: Article

References (50)

1. Ågren H. Life at risk: markers of suicidality in depression. Psychiatr. Dev. 1 1 (1983) 87-103
2. Ågren H., Mefford I.N., Rudorfer M.V., Linnoila M., and Potter W.Z. Interacting neurotransmitter systems. A non-experimental approach to the 5HIAA-HVA correlation in human CSF. J. Psychiatr. Res. 20 3 (1986) 175-193
3. Arango V., Underwood M.D., and Mann J.J. Alterations in monoamine receptors in the brain of suicide victims. J. Clin. Psychopharmacol. 12 2 Suppl (1992) 8S-12S
4. Arango V., Underwood M.D., and Mann J.J. Serotonin brain circuits involved in major depression and suicide. Prog. Brain Res. 136 (2002) 443-453
5. Åsberg M. Neurotransmitters and suicidal behavior. The evidence from cerebrospinal fluid studies. Ann. N. Y. Acad. Sci. 836 (1997) 158-181
6. Åsberg M., Träskman L., and Thoren P. 5-HIAA in the cerebrospinal fluid. A biochemical suicide predictor?. Arch. Gen. Psychiatry 33 10 (1976) 1193-1197
7. Banki C.M., Arato M., Papp Z., and Kurcz M. Biochemical markers in suicidal patients. Investigations with cerebrospinal fluid amine metabolites and neuroendocrine tests. J. Affect. Disord. 6 3-4 (1984) 341-350
8. Banki C.M., Arato M., and Kilts C.D. Aminergic studies and cerebrospinal fluid cations in suicide. Ann. N. Y. Acad. Sci. 487 (1986) 221-230
9. Bjerkenstedt L., Gullberg B., Härnryd C., and Sedvall G. Monoamine metabolite levels in cerebrospinal fluid of psychotic women treated with melperone or thiothixene. Arch. Psychiatr. Nervenkr. 224 2 (1977) 107-118
10. Carlborg A., Jokinen J., Jönsson E.G., Nordström A.L., and Nordström P. Long-term suicide risk in schizophrenia spectrum psychoses: survival analysis by gender. Arch. Suicide Res. 12 4 (2008) 347-351
11. Cohen S., Lavelle J., Rich C.L., and Bromet E. Rates and correlates of suicide attempts in first-admission psychotic patients. Acta Psychiatr. Scand. 90 3 (1994) 167-171
12. Cooper S.J., Kelly C.B., and King D.J. 5-Hydroxyindoleacetic acid in cerebrospinal fluid and prediction of suicidal behaviour in schizophrenia. Lancet 340 8825 (1992) 940-941
13. Drake R.E., and Ehrlich J. Suicide attempts associated with akathisia. Am. J. Psychiatry 142 4 (1985) 499-501
14. Ekholm B., Ekholm A., Adolfsson R., Vares M., Ösby U., Sedvall G.C., and Jönsson E.G. Evaluation of diagnostic procedures in Swedish patients with schizophrenia and related psychoses. Nord. J. Psychiatry 59 6 (2005) 457-464
15. Engström G., Alling C., Blennow K., Regnell G., and Träskman-Bendz L. Reduced cerebrospinal HVA concentrations and HVA/5-HIAA ratios in suicide attempters. Monoamine metabolites in 120 suicide attempters and 47 controls. Eur. Neuropsychopharmacol. 9 5 (1999) 399-405
16. Gottfries C.G., Gottfries I., Johansson B., Olsson R., Persson T., Roos B.E., and Sjöström R. Acid monoamine metabolites in human cerebrospinal fluid and their relations to age and sex. Neuropharmacology 10 6 (1971) 665-672
17. Härnryd C., Bjerkenstedt L., Gullberg B., Oxenstierna G., Sedvall G., and Wiesel F.A. Time course for effects of sulpiride and chlorpromazine on monoamine metabolite and prolactin levels in cerebrospinal fluid from schizophrenic patients. Acta Psychiatr. Scand. Suppl. 311 (1984) 75-92
18. Harris E.C., and Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. Br. J. Psychiatry 170 (1997) 205-228
19. Hawton K., Sutton L., Haw C., Sinclair J., and Deeks J.J. Schizophrenia and suicide: systematic review of risk factors. Br. J. Psychiatry 187 (2005) 9-20
20. Heilä H., Isometsä E.T., Henriksson M.M., Heikkinen M.E., Marttunen M.J., and Lönnqvist J.K. Suicide victims with schizophrenia in different treatment phases and adequacy of antipsychotic medication. J. Clin. Psychiatry 60 3 (1999) 200-208
21. Jokinen J., Nordström A.L., and Nordström P. The relationship between CSF HVA/5-HIAA ratio and suicide intent in suicide attempters. Arch. Suicide Res. 11 2 (2007) 187-192
22. Lemus C.Z., Lieberman J.A., Johns C.A., Pollack S., Bookstein P., and Cooper T.B. CSF 5-hydroxyindoleacetic acid levels and suicide attempts in schizophrenia. Biol. Psychiatry 27 8 (1990) 926-929
23. Lester D. The concentration of neurotransmitter metabolites in the cerebrospinal fluid of suicidal individuals: a meta-analysis. Pharmacopsychiatry 28 2 (1995) 45-50
24. Mann J.J. Neurobiology of suicidal behaviour. Nat. Rev. Neurosci. 4 10 (2003) 819-828
25. Mann J.J., Waternaux C., Haas G.L., and Malone K.M. Toward a clinical model of suicidal behavior in psychiatric patients. Am. J. Psychiatry 156 2 (1999) 181-189
26. Mann J.J., Currier D., Stanley B., Oquendo M.A., Amsel L.V., and Ellis S.P. Can biological tests assist prediction of suicide in mood disorders?. Int. J. Neuropsychopharmacol. 9 4 (2006) 465-474
27. McGirr A., Tousignant M., Routhier D., Pouliot L., Chawky N., Margolese H.C., and Turecki G. Risk factors for completed suicide in schizophrenia and other chronic psychotic disorders: a case-control study. Schizophr. Res. 84 1 (2006) 132-143
28. Meltzer H.Y., Alphs L., Green A.I., Altamura A.C., Anand R., Bertoldi A., Bourgeois M., Chouinard G., Islam M.Z., Kane J., Krishnan R., Lindenmayer J.P., and Potkin S. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch. Gen. Psychiatry 60 1 (2003) 82-91
29. Modestin J., Dal Pian D., and Agarwalla P. Clozapine diminishes suicidal behavior: a retrospective evaluation of clinical records. J. Clin. Psychiatry 66 4 (2005) 534-538
30. Ninan P.T., van Kammen D.P., Scheinin M., Linnoila M., Bunney Jr. W.E., and Goodwin F.K. CSF 5-hydroxyindoleacetic acid levels in suicidal schizophrenic patients. Am. J. Psychiatry 141 4 (1984) 566-569
31. Nordström P., Samuelsson M., Åsberg M., Träskman-Bendz L., Åberg-Wistedt A., Nordin C., and Bertilsson L. CSF 5-HIAA predicts suicide risk after attempted suicide. Suicide Life-threat. Behav. 24 1 (1994) 1-9
32. Nordström A.L., Farde L., Nyberg S., Karlsson P., Halldin C., and Sedvall G. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am. J. Psychiatry 152 10 (1995) 1444-1449
33. Pickar D., Roy A., Breier A., Doran A., Wolkowitz O., Colison J., and Agren H. Suicide and aggression in schizophrenia. Neurobiologic correlates. Ann. N. Y. Acad. Sci. 487 (1986) 189-196
34. Placidi G.P., Oquendo M.A., Malone K.M., Huang Y.Y., Ellis S.P., and Mann J.J. Aggressivity, suicide attempts, and depression: relationship to cerebrospinal fluid monoamine metabolite levels. Biol. Psychiatry 50 10 (2001) 783-791
35. Roggenbach J., Muller-Oerlinghausen B., and Franke L. Suicidality, impulsivity and aggression-is there a link to 5HIAA concentration in the cerebrospinal fluid?. Psychiatry Res. 113 1-2 (2002) 193-206
36. Roy A., Ninan P., Mazonson A., Pickar D., Van Kammen D., Linnoila M., and Paul S.M. CSF monoamine metabolites in chronic schizophrenic patients who attempt suicide. Psychol. Med. 15 2 (1985) 335-340
37. Roy A., Ågren H., Pickar D., Linnoila M., Doran A.R., Cutler N.R., and Paul S.M. Reduced CSF concentrations of homovanillic acid and homovanillic acid to 5-hydroxyindoleacetic acid ratios in depressed patients: relationship to suicidal behavior and dexamethasone nonsuppression. Am. J. Psychiatry 143 12 (1986) 1539-1545
38. Roy-Byrne P., Post R.M., Rubinow D.R., Linnoila M., Savard R., and Davis D. CSF 5HIAA and personal and family history of suicide in affectively ill patients: a negative study. Psychiatry Res. 10 4 (1983) 263-274
39. Sedvall G.C., and Wode-Helgodt B. Aberrant monoamine metabolite levels in CSF and family history of schizophrenia. Their relationships in schizophrenic patients. Arch. Gen. Psychiatry 37 10 (1980) 1113-1116
40. Sher L., Carballo J.J., Grunebaum M.F., Burke A.K., Zalsman G., Huang Y.Y., Mann J.J., and Oquendo M.A. A prospective study of the association of cerebrospinal fluid monoamine metabolite levels with lethality of suicide attempts in patients with bipolar disorder. Bipolar Disord. 8 5 Pt 2 (2006) 543-550
41. Sinclair J.M., Mullee M.A., King E.A., and Baldwin D.S. Suicide in schizophrenia: a retrospective case-control study of 51 suicides. Schizophr. Bull. 30 4 (2004) 803-811
42. Stanley M., and Mann J.J. Increased serotonin-2 binding sites in frontal cortex of suicide victims. Lancet 1 8318 (1983) 214-216
43. Stanley M., Virgilio J., and Gershon S. Tritiated imipramine binding sites are decreased in the frontal cortex of suicides. Science 216 4552 (1982) 1337-1339
44. Swahn C.G., Sandgarde B., Wiesel F.A., and Sedvall G. Simultaneous determination of the three major monoamine metabolites in brain tissue and body fluids by a mass fragmentographic method. Psychopharmacology (Berl) 48 2 (1976) 147-153
45. Tidemalm D., Langström N., Lichtenstein P., and Runeson B. Risk of suicide after suicide attempt according to coexisting psychiatric disorder: Swedish cohort study with long term follow-up. BMJ 337 (2008) a2205
46. Träskman L., Åsberg M., Bertilsson L., and Sjöstrand L. Monoamine metabolites in CSF and suicidal behavior. Arch. Gen. Psychiatry 38 6 (1981) 631-636
47. van Praag H.M. CSF 5-HIAA and suicide in non-depressed schizophrenics. Lancet 2 8356 (1983) 977-978
48. Vares M., Ekholm A., Sedvall G.C., Hall H., and Jönsson E.G. Characterization of patients with schizophrenia and related psychoses: evaluation of different diagnostic procedures. Psychopathology 39 6 (2006) 286-295
49. Wode-Helgodt B., and Sedvall G. Correlations between height of subject and concentrations of monoamine metabolites in cerebrospinal fluid from psychotic men and women. Commun. Psychopharmacol. 2 2 (1978) 177-183
50. Wode-Helgodt B., Fyrö B., Gullberg B., and Sedvall G. Effect of chlorpromazine treatment on monoamine metabolite levels in cerebrospinal fluid of psychotic patients. Acta Psychiatr. Scand. 56 2 (1977) 129-142